vs
Pacira BioSciences, Inc.（PCRX）与WSFS FINANCIAL CORP（WSFS）财务数据对比。点击上方公司名可切换其他公司
WSFS FINANCIAL CORP的季度营收约是Pacira BioSciences, Inc.的1.6倍（$275.3M vs $177.4M），WSFS FINANCIAL CORP净利率更高（31.5% vs 1.6%，领先29.9%），WSFS FINANCIAL CORP同比增速更快（7.5% vs 5.0%），过去两年WSFS FINANCIAL CORP的营收复合增速更高（1.7% vs -0.2%）
Pacira BioSciences是一家专科制药企业，专注于非阿片类疼痛管理药物的研发与商业化，核心产品线面向术后镇痛场景，服务以美国为主的医院、门诊手术中心等医疗服务机构，同时推进部分国际市场的拓展工作。
WSFS金融集团是一家金融服务企业，核心子公司WSFS银行是总部位于特拉华州及大特拉华谷地区规模最大、经营历史最久的本地管理银行与财富管理机构。集团共运营115个网点，其中88个为银行网点，分布在宾夕法尼亚、特拉华、新泽西、佛罗里达、弗吉尼亚、内华达六州，提供全面金融服务。
PCRX vs WSFS — 直观对比
营收规模更大
WSFS
是对方的1.6倍
$177.4M
营收增速更快
WSFS
高出2.5%
5.0%
净利率更高
WSFS
高出29.9%
1.6%
两年增速更快
WSFS
近两年复合增速
-0.2%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $177.4M | $275.3M |
| 净利润 | $2.9M | $86.8M |
| 毛利率 | — | — |
| 营业利润率 | 3.9% | — |
| 净利率 | 1.6% | 31.5% |
| 营收同比 | 5.0% | 7.5% |
| 净利润同比 | — | 31.7% |
| 每股收益（稀释后） | $0.07 | $1.64 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PCRXWSFS
| Q1 26 | $177.4M | $275.3M | ||
| Q4 25 | $196.9M | $271.9M | ||
| Q3 25 | $179.5M | $270.5M | ||
| Q2 25 | $181.1M | $267.5M | ||
| Q1 25 | $168.9M | $256.1M | ||
| Q4 24 | $187.3M | $261.5M | ||
| Q3 24 | $168.6M | $267.7M | ||
| Q2 24 | $178.0M | $266.0M |
净利润PCRXWSFS
| Q1 26 | $2.9M | $86.8M | ||
| Q4 25 | — | $72.7M | ||
| Q3 25 | $5.4M | $76.4M | ||
| Q2 25 | $-4.8M | $72.3M | ||
| Q1 25 | $4.8M | $65.9M | ||
| Q4 24 | — | $64.2M | ||
| Q3 24 | $-143.5M | $64.4M | ||
| Q2 24 | $18.9M | $69.3M |
毛利率PCRXWSFS
| Q1 26 | — | — | ||
| Q4 25 | 79.5% | — | ||
| Q3 25 | 80.9% | — | ||
| Q2 25 | 77.4% | — | ||
| Q1 25 | 79.7% | — | ||
| Q4 24 | 78.7% | — | ||
| Q3 24 | 76.9% | — | ||
| Q2 24 | 75.1% | — |
营业利润率PCRXWSFS
| Q1 26 | 3.9% | — | ||
| Q4 25 | 1.2% | 35.8% | ||
| Q3 25 | 3.5% | 37.3% | ||
| Q2 25 | 4.7% | 35.7% | ||
| Q1 25 | 1.2% | 34.0% | ||
| Q4 24 | 13.2% | 32.3% | ||
| Q3 24 | -82.8% | 31.9% | ||
| Q2 24 | 15.9% | 34.0% |
净利率PCRXWSFS
| Q1 26 | 1.6% | 31.5% | ||
| Q4 25 | — | 26.7% | ||
| Q3 25 | 3.0% | 28.3% | ||
| Q2 25 | -2.7% | 27.0% | ||
| Q1 25 | 2.8% | 25.7% | ||
| Q4 24 | — | 24.6% | ||
| Q3 24 | -85.1% | 24.1% | ||
| Q2 24 | 10.6% | 26.0% |
每股收益（稀释后）PCRXWSFS
| Q1 26 | $0.07 | $1.64 | ||
| Q4 25 | $0.05 | $1.33 | ||
| Q3 25 | $0.12 | $1.37 | ||
| Q2 25 | $-0.11 | $1.27 | ||
| Q1 25 | $0.10 | $1.12 | ||
| Q4 24 | $0.38 | $1.08 | ||
| Q3 24 | $-3.11 | $1.08 | ||
| Q2 24 | $0.39 | $1.16 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $144.3M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $653.9M | $2.7B |
| 总资产 | $1.2B | $22.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PCRXWSFS
| Q1 26 | $144.3M | — | ||
| Q4 25 | $238.4M | $1.7B | ||
| Q3 25 | $246.3M | — | ||
| Q2 25 | $445.9M | — | ||
| Q1 25 | $493.6M | — | ||
| Q4 24 | $484.6M | $1.2B | ||
| Q3 24 | $453.8M | — | ||
| Q2 24 | $404.2M | — |
总债务PCRXWSFS
| Q1 26 | — | — | ||
| Q4 25 | $372.2M | — | ||
| Q3 25 | $376.7M | — | ||
| Q2 25 | $580.5M | — | ||
| Q1 25 | $583.4M | — | ||
| Q4 24 | $585.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益PCRXWSFS
| Q1 26 | $653.9M | $2.7B | ||
| Q4 25 | $693.1M | $2.7B | ||
| Q3 25 | $727.2M | $2.8B | ||
| Q2 25 | $757.8M | $2.7B | ||
| Q1 25 | $798.5M | $2.7B | ||
| Q4 24 | $778.3M | $2.6B | ||
| Q3 24 | $749.6M | $2.7B | ||
| Q2 24 | $879.3M | $2.5B |
总资产PCRXWSFS
| Q1 26 | $1.2B | $22.1B | ||
| Q4 25 | $1.3B | $21.3B | ||
| Q3 25 | $1.3B | $20.8B | ||
| Q2 25 | $1.5B | $20.8B | ||
| Q1 25 | $1.6B | $20.5B | ||
| Q4 24 | $1.6B | $20.8B | ||
| Q3 24 | $1.5B | $20.9B | ||
| Q2 24 | $1.6B | $20.7B |
负债/权益比PCRXWSFS
| Q1 26 | — | — | ||
| Q4 25 | 0.54× | — | ||
| Q3 25 | 0.52× | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.73× | — | ||
| Q4 24 | 0.75× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
WSFS
暂无分部数据
